As precision medicine gains steam, the question arises: how can reimbursement models evolve to support these often costly therapies and ensure patient access is not blocked? Drugmakers and payers are working together to find some answers.
Researchers at Columbia University have developed an algorithm that can determine how an individual will react to a drug - paving the way for drugs with fewer side effects, or finding new therapeutic uses for existing medications.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Researchers have found a fertile source for new antibiotics: Vaginal bacteria. It’s a Darwinian world down there, with “good,” antibiotic-producing bacteria present to combat more malevolent microcritters like MRSA. So when plumbing the depths of the microbiome, University of California, San Francisco researchers essentially discovered a new antibiotic. Their findings were published Sept. 11 in Cell. Interestingly, the news stretches […]